News
Print
May 6, 2009
ADVAXIS EXPLORES NEW DRUG LICENSING OPPORTUNITIES
The Sage Group to Help Introduce and Develop Potential Strategic Partnership Candidates
North Brunswick, NJ – May 6, 2009 – Advaxis, Incorporated (OTCBB: ADXS) has entered into a formal business agreement with the Sage Group to introduce potential partnership candidates and develop new licensing opportunities.
The Sage Group is a leader in the provision of strategic and transactional consultancy services to US and European healthcare and life science companies advising on global strategic partnering opportunities.
"With the increasing acceptance of our technology in the experimental medical community it is an opportune time to identify possible strategic relationships," commented Advaxis CEO Thomas A. Moore. "As our current licensing negotiations develop, we also seek to find additional opportunities to commercialize our platform as expeditiously as possible, and the Sage Group’s expertise will help us find the best fit among potential partners, both near and long term."
About Sage Group, Inc.
Sage is a senior-level health care, technology oriented, strategy and transaction advisory firm formed in 1994. The principals of Sage are seven highly experienced healthcare executives, each of whom has substantial strategic, analytical and hands-on operating experience, as well as extensive backgrounds in licensing – in and out, corporate partnering and M&A. In addition, Sage’s advisors and senior directors have extensive knowledge in the clinical, regulatory and product development disciplines. Sage’s principals have played key leadership roles as founders/CEOs in a number of emerging biomedical companies and senior executives in multinational corporations. They have also played key consulting roles in corporate partnering/acquisition and licensing strategies of emerging and mid-sized companies.
Since 1994, Sage has advised on well over $1 billion worth of M&A and licensing transactions for various pharmaceutical and biotechnology companies. For further information on The Sage Group, please visit their website located at www.sagehealthcare.com. Interested parties may contact R. Douglas Hulse at 908-231-9644 x704.
About Advaxis, Incorporated
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
